CN108840917A - Dermatophagoides pteronyssinus allergen Der p 30 and its preparation method and application - Google Patents
Dermatophagoides pteronyssinus allergen Der p 30 and its preparation method and application Download PDFInfo
- Publication number
- CN108840917A CN108840917A CN201810601060.7A CN201810601060A CN108840917A CN 108840917 A CN108840917 A CN 108840917A CN 201810601060 A CN201810601060 A CN 201810601060A CN 108840917 A CN108840917 A CN 108840917A
- Authority
- CN
- China
- Prior art keywords
- dermatophagoides pteronyssinus
- allergen der
- der
- pteronyssinus allergen
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43513—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae
- C07K14/43531—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from arachnidae from mites
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/35—Allergens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/43504—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates
- G01N2333/43552—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects
- G01N2333/43582—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from invertebrates from insects from mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Insects & Arthropods (AREA)
- General Engineering & Computer Science (AREA)
- Urology & Nephrology (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Cell Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Plant Pathology (AREA)
Abstract
The present invention provides a kind of dermatophagoides pteronyssinus allergen Der p 30, the dermatophagoides pteronyssinus allergen Der p 30 includes such as SEQ ID NO:Amino acid sequence shown in 1 and with such as SEQ ID NO:Amino acid sequence shown in 1 has at least one of the amino acid sequence of at least 98% homology, it is with a wide range of applications in the anaphylactia caused by dust acarid allergen vaccine and prevention, diagnosing and treating dust mite of dermatophagoides pteronyssinus allergen Der p 30, the especially drug of anaphylactia caused by the 30th component of dermatophagoides pteronyssinus.The present invention passes through gene cloning, Protein expression and purification, the dermatophagoides pteronyssinus allergen Der p 30 recombinated, purity of protein height, abundance, be conducive to subsequent scientific research to use and a large amount of application and preparations, the especially application in the drug of the anaphylactia caused by dust acarid allergen vaccine and preparation prevention, diagnosing and treating dust mite.
Description
Technical field
The present invention relates to field of biomedicine, in particular to dermatophagoides pteronyssinus allergen Der p 30 and preparation method thereof and answer
With.
Background technique
Allergic disease (anaphylactia) is considered the great hygienic knowledge of our times by the World Health Organization
Topic, the total incidence of countries in the world allergic disease are up to 10-30%.Its disease incidence was gradually increasing in recent years.?
Cause in the numerous inhalant allergens of anaphylactia, dust mite is to lead to the most important factor of allergic disease.Hair at present
Existing dust mite (Der-matophagoides farinae, Der f), dermatophagoides pteronyssinus (Dermato-phayoides
Pteronyssinus, Der p) it is indoor advantage sensitization mite class widely distributed in world wide.
Due to dust mite system Medical arthropod, structure and complicated component, although people tentatively reflect from hundreds of albumen
Several allergy ultimate constituents are made, and researches show that dust mites also to contain other a variety of allergy ultimate constituents；And these allergy ultimate constituents pair
There is important meaning to the reagent for diagnosing and treating dust mite allergy in the immunopathogenesis of research dust mite allergy, and research and development
Justice.
Summary of the invention
In view of this, the present invention provides dermatophagoides pteronyssinus allergen Der p 30, pass through gene cloning, protein expression and pure
Change, the dermatophagoides pteronyssinus allergen Der p 30 recombinated, dermatophagoides pteronyssinus allergen Der p 30 are in dust acarid allergen vaccine and in advance
Anti-, anaphylactia caused by the 30th component of anaphylactia more particularly to dermatophagoides pteronyssinus caused by diagnosing and treating dust mite medicine
It is with a wide range of applications in object.
In a first aspect, the present invention provides a kind of dermatophagoides pteronyssinus allergen Der p 30, the dermatophagoides pteronyssinus allergen Der p
30 include such as SEQ ID NO:Amino acid sequence shown in 1 and with such as SEQ ID NO:Amino acid sequence shown in 1 has at least
At least one of the amino acid sequence of 98% homology.
In the present invention, the dermatophagoides pteronyssinus allergen Der p 30 is the 30th component of dermatophagoides pteronyssinus allergen.
In the present invention, term " homology " shows any two (or more than two) peptide, polypeptide or protein sequence tool
There is the amino acid sequence of (" % is homologous ") and " identical " each other to a certain extent.Known meter can be used in this degree of homology
Calculation machine program determines.Specifically, the BLAST tool that can be, but not limited in ncbi database can be used to determine homology.
In the present invention, the homology is at least 98%.Further alternative, the homology is at least 99%.
Optionally, the dermatophagoides pteronyssinus allergen Der p 30 further includes and such as SEQ ID NO:Amino acid sequence shown in 1
Dermatophagoides pteronyssinus allergen with immune cross-reactivity.As described in the present invention, term " immune cross-reactivity " is in industry
It is conventional to understand, when a kind of antibody can not synantigen not fully identical as molecular structure but having similar antigenic determinant
Reaction, referred to as immunological cross-reaction；There is no immune cross-reactivity between synantigen.
Optionally, the encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 includes coding such as SEQ ID NO:Shown in 1
The nucleotide sequence of amino acid sequence.
Further alternative, the encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 includes such as SEQ ID NO:Shown in 2
Nucleotide sequence.
Optionally, the encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 should consider degeneracy base, i.e., such as SEQ ID
NO:The encoding gene of amino acid sequence shown in 1 includes such as SEQ ID NO:Nucleotide sequence shown in 2, protection scope are also answered
The protection and SEQ ID NO:2 nucleotide sequences with base degeneracy matter, the corresponding amino acid sequence of these nucleotide sequences
Column remain as SEQ ID NO:1.
The dermatophagoides pteronyssinus allergen Der p 30 that first aspect present invention provides is in dust acarid allergen vaccine and prevention, diagnosis
It is with a wide range of applications in the drug of anaphylactia caused by treatment dust mite.
Second aspect, the present invention provides a kind of recombinant vector, the recombinant vector includes room as described in relation to the first aspect
The encoding gene of dust mite allergen Der p 30.
Optionally, the recombinant vector includes at least one of recombinant expression carrier and recombinant cloning vector.Further
Optionally, I restriction enzyme site of BamH I and Xho is contained in the recombinant vector, specifically, the dermatophagoides pteronyssinus allergen Der p 30
Encoding gene be inserted between I restriction enzyme site of BamH I and Xho.Optionally, the coding of the dermatophagoides pteronyssinus allergen Der p 30
When gene is inserted into carrier, initiation codon can be added (such as in 5 ' ends of the encoding gene of the dermatophagoides pteronyssinus allergen Der p 30
ATG), terminator codon (such as TAA) can be added in 3 ' ends.
Optionally, contain purification tag in the recombinant vector, specifically can be, but not limited to mark for His label, GST
Label, SUMO label.
Optionally, the recombinant vector can be, but not limited to as in pET-32a, pGEX-6P-1, pPIC-9K, pPIC-Z α
At least one.
The third aspect, the present invention provides a kind of host cell, the host cell includes the weight as described in second aspect
Group carrier.
Optionally, the host cell includes at least one of cloning host cell and expression host cell.Specifically,
The host cell can be, but not limited to as Escherichia coli, saccharomyces cerevisiae, Pichia pastoris, zooblast, plant cell.Specifically
, it can be, but not limited to as bacillus coli DH 5 alpha, Escherichia coli Top10, Escherichia coli Orgami (DE3), Pichia pastoris
GS115, Pichia pastoris SMD1168.
Fourth aspect, the present invention provides the preparation methods of dermatophagoides pteronyssinus allergen Der p 30 a kind of, including：
(1) encoding gene of dermatophagoides pteronyssinus allergen Der p 30 is prepared and obtains, the dermatophagoides pteronyssinus allergen Derp's 30
Encoding gene includes coding such as SEQ ID NO：The nucleotide sequence of amino acid sequence shown in 1；
(2) encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 is inserted into expression vector, obtains recombinant plasmid；
(3) recombinant plasmid is gone in expression host cell, carries out protein expression and purification, obtained dermatophagoides pteronyssinus and become
Answer former Der p 30.
Optionally, the encoding gene for preparing and obtaining dermatophagoides pteronyssinus allergen Der p 30 includes：It is total to extract dermatophagoides pteronyssinus
Albumen separates and identifies to obtain the dermatophagoides pteronyssinus allergen Der p 30, obtains the dermatophagoides pteronyssinus allergen by PCR amplification
The encoding gene of Der p 30.
Optionally, it is described to prepare dermatophagoides pteronyssinus allergen when the host cell as described in fourth aspect is expression host cell
The method of Der p 30 can also be：The host cell as described in terms of the 5th is cultivated, by the expression and purifying of protein,
Obtain the dermatophagoides pteronyssinus allergen Der p 30.Specifically, can be, but not limited to when the host cell be Bacillus coli expression
When host cell, the Escherichia coli are cultivated in LB culture medium, and isopropylthio galactolipin is added during the cultivation process
Glycosides carries out 30 inducing expression of dermatophagoides pteronyssinus allergen Der p, after centrifugation, cracking, bacteriolyze, ultrasound, separate by nickel column pure
Change, obtains dermatophagoides pteronyssinus allergen Derp 30.
The preparation method for the dermatophagoides pteronyssinus allergen Der p 30 that fourth aspect present invention provides is easy to operate, it is easy to accomplish,
It is at low cost, it can be used for large-scale industrial production；Compared with natural dermatophagoides pteronyssinus allergen, dermatophagoides pteronyssinus made from the preparation method becomes
Answer former 30 purity is high of Der p, yield good, bioactivity is strong, while being not easily susceptible to the pollution of exogenous noxious material, stability
It is good, it can be used for studying allergic reaction caused by the immunopathogenesis of dust mite allergy, especially the 30th component of dermatophagoides pteronyssinus allergen；
It is of great significance in dust acarid allergen vaccine and research and development to diagnose and treat the drug of dust mite allergy.
5th aspect, the present invention provides a kind of composition, including as described in relation to the first aspect or as described in fourth aspect
Preparation method made from dermatophagoides pteronyssinus allergen Der p 30.
Optionally, the composition further includes pharmaceutically acceptable carrier.It is further alternative, it is described pharmaceutically to connect
The carrier received includes at least one of solvent, polymer and liposome, but not limited to this.It is further optional, it is described molten
Agent includes but is not limited to water, physiological saline and other non-aqueous solvents.Specifically, the polymer can be, but not limited to for
Polylysine, polyethyleneimine and its modifier, chitosan, polylactic acid, gelatin, cyclodextrin.Specifically, the liposome can be with
But it is not limited to cholesterol, beans lecithin, egg yolk lecithin.Further optional, the pharmaceutically acceptable carrier is also
Including one of diluent and excipient or a variety of.Optionally, the diluent include starch, carbohydrate, cellulose family and
One of inorganic salts are a variety of.The excipient includes binder, filler, lubricant in tablet, and semisolid preparation is soft
Base portion in paste, creme, preservative, antioxidant, corrigent, aromatic, cosolvent, emulsifier in liquid preparation,
At least one of colorant.
In the present invention, the composition can also include other active components, and the active constituent is according to the combination
The purposes of object is selected, and is not limited thereto.
6th aspect, the present invention provides a kind of dermatophagoides pteronyssinus allergen Der p 30, such as second as described in relation to the first aspect
Recombinant vector described in aspect, the host cell as described in the third aspect, room made from the preparation method as described in fourth aspect
Dust mite allergen Der p 30 or composition as described in terms of the 5th in dust acarid allergen vaccine and prevention, diagnose and control
Treat the application in the drug of anaphylactia caused by dust mite.
Application especially in the drug of the anaphylactia caused by prevention, the 30th component of diagnosing and treating dermatophagoides pteronyssinus.
It is further alternative, prevention, diagnosing and treating allergic asthma, rhinitis, chronic urticaria drug in application.
Optionally, the drug is at least one of chemical classes drug and bio-pharmaceutical.It is further alternative, the life
Object drug is one of polypeptide drug, protein drug and genomic medicine or a variety of.
Optionally, the drug further includes allergy caused by other pharmaceutically acceptable prevention, diagnosing and treating dust mites
The active constituent of property disease.
Optionally, the form of the drug includes tablet, capsule, pulvis, granule, pill, syrup, solution or mixed
Suspension.
It is described application specifically can be, but not limited to for：A kind of kit is provided, includes such as first party in the kit
Dermatophagoides pteronyssinus allergen Der p 30, the recombinant vector as described in second aspect, the host as described in the third aspect described in face are thin
Born of the same parents or the composition as described in fourth aspect.
Beneficial effects of the present invention：
(1) present invention firstly discovers that and obtain dermatophagoides pteronyssinus allergen Der p 30, dust mite allergen component is enriched, in dirt
Anaphylactia caused by mite allergen vaccine and prevention, diagnosing and treating dust mite, especially the 30th component of dermatophagoides pteronyssinus cause
Anaphylactia drug in be with a wide range of applications；
(2) present invention is by gene cloning, Protein expression and purification, the dermatophagoides pteronyssinus allergen Der p 30 recombinated,
Purity of protein height, abundance, stability is high, is conducive to subsequent a large amount of preparations and research uses.
Detailed description of the invention
In order to more clearly explain the embodiment of the invention or the technical proposal in the existing technology, to embodiment or will show below
There is attached drawing needed in technical description to be briefly described, it should be apparent that, the accompanying drawings in the following description is only this
Some embodiments of invention for those of ordinary skill in the art without creative efforts, can be with
It obtains other drawings based on these drawings.
Fig. 1 is the 30 double digestion figure of recombinant plasmid pET-32a-Der p that the embodiment of the present invention 1 provides；
Fig. 2 is the 30 protein adhesive figure of Der p that the embodiment of the present invention 1 provides, and wherein (a) is Der p30 without pure in Fig. 2
The protein adhesive figure of change, (b) is 30 protein adhesive figure of Der p after purification in Fig. 2.
Specific embodiment
Following will be combined with the drawings in the embodiments of the present invention, and technical solution in the embodiment of the present invention carries out clear, complete
Site preparation description, it is clear that described embodiments are only a part of the embodiments of the present invention, instead of all the embodiments.It is based on
Embodiment in the present invention, it is obtained by those of ordinary skill in the art without making creative efforts every other
Embodiment shall fall within the protection scope of the present invention.
In embodiments of the present invention, described " dust mite allergen Der p 30 ", " the dermatophagoides pteronyssinus allergen Derp 30 " with
" the Der p 30 " can be interchanged.
The preparation of one dermatophagoides pteronyssinus allergen Der p 30 of embodiment
1, construction of recombinant vector
Dermatophagoides pteronyssinus total protein is extracted, separates and identifies to obtain dermatophagoides pteronyssinus allergen Der p 30, dermatophagoides pteronyssinus is obtained by PCR
The nucleotide sequence of allergen Der p 30 has 324 base compositions (containing terminator codon) as shown in SEQ ID NO.1,
108 amino acid sequences (containing terminator codon) is encoded, and is by the relative molecular mass that bioinformatics analysis declines its albumen
28kD, isoelectric point 5.24.
The N-terminal of the nucleotide sequence of dermatophagoides pteronyssinus allergen Der p 30 is added into I digestion of BamH by gene synthesis technology
Site and its protection base add I restriction enzyme site of Xho and its protection base in C-terminal, I double digestion of BamH I and Xho are carried out to it,
BamH I and I double digestion of Xho are carried out to pET-32a simultaneously, the digestion products of the two carry out agarose gel electrophoresis verifying, sequence
It is recycled after size is correct, and the double enzyme digestion product of the two is mixed and is added T4DNA Ligase (ligase),
It is attached reaction 16h at 16 DEG C, obtains recombinant plasmid pET-32a-Der p 30, then converts into Escherichia coli Top10,
Bacterium solution is applied on the LB plate of the benzyl containing ammonia, 37 DEG C of overnight incubations.Picking single colonie, extract plasmid after carry out again double digestion and
Sequence verification, wherein as shown in Figure 1, wherein M indicates protein molecular weight standard (marker), 1 swimming lane indicates double digestion result
Double digestion figure has purpose matrix tapes in 324bp or so, is consistent with Der p30 theoretical molecular weight, while sequencing result shows mesh
Gene insertion it is correct.
2, the expression and purifying of Der p 30
The correct conversion of pET-32a-Der p 30 will be sequenced and express bacterium to the Orgami handled through calcium chloride competence, pass through
Ammonia benzyl plate screening, picking positive bacterium colony are incubated overnight.It is secondary shake bacterium after, the IPTG that final concentration of 1mmol/L is added is lured
It leads, 37 DEG C, collect thallus after 200 turns/min induction 4h, ultrasonication takes supernatant precipitating to carry out 12%SDS-PAGE points respectively
Analysis, to determine albumen solubility.Ni is carried out with FPLC again2+Affinitive layer purification, including column is sufficiently washed with equilibrium liquid, then use respectively
The imidazoles equilibration buffer containing 40mmol/L, 300mmol/L is eluted, and is collected each secondary eluent and is carried out SDS-PAGE analysis, obtains
Obtain Der p 30.As a result as shown in Fig. 2, wherein M indicates protein molecular weight standard (marker) in (a) in Fig. 2,1 swimming lane table
Show the albumen distribution in pre-induction medium, 2 swimming lanes indicate the albumen distribution after inducing in culture medium, and 3 swimming lanes indicate in supernatant
Albumen distribution, 4 swimming lanes indicate precipitating in albumen distribution, it can be seen that the successful inducing expression of Der p 30.Using Ni2+Parent
After chromatographic purifying, in Fig. 2 shown in (b), wherein M indicates protein molecular weight standard (marker), and 1 swimming lane indicates after purification
30 albumen figure of Der p, 30 albumen size of Der p be 28kD, be consistent with prediction result, and be soluble protein.
1 allergenicity of effect example detects (ELISA)
Every hole coating 30 100 μ L of Der p (1 μ g/mL) in 96 orifice plates, 4 DEG C of 3%BSA closings are overnight.With dermatophagoides pteronyssinus
The serum (1 of autopath:50 dilution proportion) it is primary antibody, primary antibody is normal human serum (4 parts), 37 DEG C of incubations in control group
2h.The anti human IgE (1 of 100 μ L biotin labelings is added in every hole later:2000 dilution proportions), 37 DEG C of incubation 2h.Cleaning 5 times, often
The Streptavidin (1 of 100 μ L HRP label is added in hole:5000 dilution proportions), 37 DEG C of incubation 1h.37 DEG C of incubations after colour developing
Then 10min terminates reaction with the concentrated sulfuric acid of 2mol/L.Its absorbance at 450nm is detected with automatic microplate reader, analyzes number
According to the light absorption value of patients serum IgE detection is higher than 2.5 times of the light absorption value of normal human serum IgE detection for the positive, and with normal
Human serum is as control, as a result, it has been found that Der p 30 has anaphylactogen.
The above disclosure is only the preferred embodiments of the present invention, cannot limit the right model of the present invention with this certainly
It encloses, those skilled in the art can understand all or part of the processes for realizing the above embodiment, and wants according to right of the present invention
Made equivalent variations is sought, is still belonged to the scope covered by the invention.
Sequence table
<110>Liu Zhigang
<120>Dermatophagoides pteronyssinus allergen Der p 30 and its preparation method and application
<160> 2
<170> SIPOSequenceListing 1.0
<210> 1
<211> 107
<212> PRT
<213>Artificial sequence (Artificial Sequence)
<400> 1
Met Lys Phe Gln Asn Gln Arg Gly Gly Arg Ile Leu Leu His Asp Ile
1 5 10 15
Pro Lys Pro Val Lys Gln Asp Trp Thr Ser Gly Leu Glu Ala Met Glu
20 25 30
Ala Ala Leu Glu Leu Glu Lys Thr Val Asn Gln Ser Leu Leu Asp Leu
35 40 45
His Gly Val Ala Thr Lys Asn Ser Asp Val Gln Phe Ala Asp Phe Leu
50 55 60
Glu Thr His Tyr Leu Thr Glu Gln Val Glu Ala Ile Lys Lys Leu Ala
65 70 75 80
Asp Tyr Val Thr Gln Leu Arg Arg Cys Gly Pro Gly Leu Gly Glu Tyr
85 90 95
Leu Phe Asp Lys His Thr Leu Gln Gly Gln Ser
100 105
<210> 2
<211> 324
<212> DNA
<213>Artificial sequence (Artificial Sequence)
<400> 2
atgaaattcc agaaccagcg tggcggccgt atcctgctgc acgatatccc gaaaccggtt 60
aaacaggatt ggaccagcgg cctggaagcg atggaagcgg cgctggaact ggaaaaaacc 120
gttaaccaga gcctgctgga tctgcacggc gttgcgacca aaaacagcga tgttcagttc 180
gcggatttcc tggaaaccca ctacctgacc gaacaggttg aagcgatcaa aaaactggcg 240
gattacgtta cccagctgcg tcgttgcggc ccgggcctgg gtgaatacct gttcgataaa 300
cacaccctgc agggccagag ctaa 324
Claims (10)
1. a kind of dermatophagoides pteronyssinus allergen Der p 30, which is characterized in that the dermatophagoides pteronyssinus allergen Der p 30 includes such as SEQ
ID NO:Amino acid sequence shown in 1 and with such as SEQ ID NO:Amino acid sequence shown in 1 has at least 98% homology
At least one of amino acid sequence.
2. dermatophagoides pteronyssinus allergen Der p 30 as described in claim 1, which is characterized in that the dermatophagoides pteronyssinus allergen Der p
30 encoding gene includes coding such as SEQ ID NO:The nucleotide sequence of amino acid sequence shown in 1.
3. dermatophagoides pteronyssinus allergen Der p 30 as claimed in claim 2, which is characterized in that the dermatophagoides pteronyssinus allergen Der p
30 encoding gene includes such as SEQ ID NO:Nucleotide sequence shown in 2.
4. a kind of recombinant vector, which is characterized in that the recombinant vector includes encoding room as described in any one of claims 1-3
The encoding gene of dust mite allergen Der p 30.
5. a kind of host cell, which is characterized in that the host cell includes recombinant vector as claimed in claim 4.
6. a kind of preparation method of dermatophagoides pteronyssinus allergen Der p 30, which is characterized in that including：
(1) prepare and obtain the encoding gene of dermatophagoides pteronyssinus allergen Der p 30, the volume of the dermatophagoides pteronyssinus allergen Der p 30
Code gene includes coding such as SEQ ID NO：The nucleotide sequence of amino acid sequence shown in 1；
(2) encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 is inserted into expression vector, obtains recombinant plasmid；
(3) recombinant plasmid is gone in expression host cell, carries out protein expression and purification, obtain dermatophagoides pteronyssinus allergen
Der p 30。
7. the preparation method of dermatophagoides pteronyssinus allergen Der p 30 as claimed in claim 6, which is characterized in that the preparation simultaneously obtains
The encoding gene of dermatophagoides pteronyssinus allergen Der p 30 includes：Dermatophagoides pteronyssinus total protein is extracted, separate and identifies to obtain dermatophagoides pteronyssinus change
Former Der p 30 is answered, the encoding gene of the dermatophagoides pteronyssinus allergen Der p 30 is obtained by PCR amplification.
8. a kind of composition, which is characterized in that any including as described in any one of claims 1-3 or such as claim 6-7
Dermatophagoides pteronyssinus allergen Der p 30 made from preparation method described in.
9. composition as claimed in claim 8, which is characterized in that the composition further includes pharmaceutically acceptable carrier.
10. dermatophagoides pteronyssinus allergen Der p 30 as described in any one of claims 1-3, recombination as claimed in claim 4 carry
Body, host cell as claimed in claim 5, the dermatophagoides pteronyssinus as made from claim 6-7 described in any item preparation methods become
Answer former Der p 30 or as the described in any item compositions of claim 8-9 dust acarid allergen vaccine and prevention, diagnosis and
Treat the application in the drug of anaphylactia caused by dust mite.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810601060.7A CN108840917B (en) | 2018-06-12 | 2018-06-12 | House dust mite allergen Der p30 and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810601060.7A CN108840917B (en) | 2018-06-12 | 2018-06-12 | House dust mite allergen Der p30 and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108840917A true CN108840917A (en) | 2018-11-20 |
| CN108840917B CN108840917B (en) | 2021-11-12 |
Family
ID=64211701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810601060.7A Active CN108840917B (en) | 2018-06-12 | 2018-06-12 | House dust mite allergen Der p30 and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108840917B (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972352A (en) * | 1987-06-17 | 1999-10-26 | Thomas; Wayne R. | Cloning of mite allergens |
| CN101432299A (en) * | 2006-04-28 | 2009-05-13 | 碧欧美公司 | House dust mite allergen |
| CN103073636A (en) * | 2013-01-29 | 2013-05-01 | 中国科学院昆明动物研究所 | Dermtophagoides farinae allergens Der f 29 and Der f 30, and genes and applications thereof |
| CN104894089A (en) * | 2015-03-27 | 2015-09-09 | 深圳大学 | Dust mite allergen and application thereof |
| CN106146640A (en) * | 2016-05-31 | 2016-11-23 | 深圳大学 | Dust mite allergen and application thereof |
-
2018
- 2018-06-12 CN CN201810601060.7A patent/CN108840917B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5972352A (en) * | 1987-06-17 | 1999-10-26 | Thomas; Wayne R. | Cloning of mite allergens |
| CN101432299A (en) * | 2006-04-28 | 2009-05-13 | 碧欧美公司 | House dust mite allergen |
| CN103073636A (en) * | 2013-01-29 | 2013-05-01 | 中国科学院昆明动物研究所 | Dermtophagoides farinae allergens Der f 29 and Der f 30, and genes and applications thereof |
| CN104894089A (en) * | 2015-03-27 | 2015-09-09 | 深圳大学 | Dust mite allergen and application thereof |
| CN106146640A (en) * | 2016-05-31 | 2016-11-23 | 深圳大学 | Dust mite allergen and application thereof |
Non-Patent Citations (3)
| Title |
|---|
| ARLIAN,L.G.等: "Group 30 mite allergen-like protein (Ferritin) [Euroglyphus maynei]", 《GENBANK: OTF74206.1》 * |
| THOMAS A. RANDALL等: "The draft genome assembly of Dermatophagoides pteronyssinus supports identification of novel allergen isoforms in Dermatophagoides species", 《INT ARCH ALLERGY IMMUNOL》 * |
| XIAO-YU LIU等: "High-quality assembly of Dermatophagoides pteronyssinus genome and transcriptome reveals a wide range of novel allergens", 《J ALLERGY CLIN IMMUNOL》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108840917B (en) | 2021-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6324952B2 (en) | αO-superfamily conotoxin peptides, pharmaceutical compositions thereof and uses thereof | |
| JP6068544B2 (en) | Hypoallergenic hybrid protein of major group 1 mite allergen and major group 2 mite allergen for use in the treatment of allergies | |
| CN110167585A (en) | Stabilized 2nd group of influenza hemagglutinin stem area tripolymer and application thereof | |
| CN106397610B (en) | The preparation method and applications of Echinococcus Granulosus Cysts multi-epitope fusion diagnosis antigen protein | |
| Van Damme et al. | Potato lectin: an updated model of a unique chimeric plant protein | |
| WO2019223749A1 (en) | Acinetobacter baumannii immunogenic protein and composition and application thereof | |
| CN106146640B (en) | Dust mite allergen and its application | |
| CN110845582B (en) | Preparation of feline parvovirus recombinant protein and monoclonal antibody thereof | |
| Lindahl | Subdominance in antibody responses: implications for vaccine development | |
| CN108892716A (en) | Dermatophagoides pteronyssinus allergen Der p 29 and its preparation method and application | |
| CN107056925A (en) | People FGF21 mutant, preparation method and the usage | |
| CN108864269A (en) | Dermatophagoides pteronyssinus allergen Der p 26 and its preparation method and application | |
| CN102307894B (en) | A variant of mite allergen and uses thereof | |
| CN113817040A (en) | Echinococcus granulosus recombinant protein and preparation method thereof | |
| CN108840917A (en) | Dermatophagoides pteronyssinus allergen Der p 30 and its preparation method and application | |
| CN110066330A (en) | A kind of imitative stichopus japonicus glucan-binding protein and its preparation method and application | |
| CN102219858A (en) | Cryptosporidium parvum CTL multi-epitope gene and fusion protein and application thereof | |
| CN105906716B (en) | Preparation and application of echovirus 9 type VP1 protein specific epitope and fusion protein thereof | |
| CN107460173A (en) | A kind of method for purifying Porcine epidemic diarrhea virus, porcine reproductive and respiratory syndrome virus or avian influenza virus | |
| CN108892715B (en) | House dust mite allergen Der p 33 and preparation method and application thereof | |
| CN108699561A (en) | Recombinant lactic acid bacteria and its purposes in oral universal influenza vaccine | |
| Teng et al. | Tyrophagus putrescentiae group 4 allergen allergenicity and epitope prediction | |
| CN108823194A (en) | A kind of dust mite albumen and its preparation method and application | |
| CN107344969A (en) | A kind of nanometer influenza vaccines and construction method and application | |
| CN103874509B (en) | Hypoallergenic variant from the main allergen Mal d 1 of apple |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |